Characterization, Kinetics, and Crystal Structures of Fructose-1,6-bisphosphate Aldolase from the Human Parasite, *Giardia lamblia*

Maryland 20850, the human parasitic protozoan *Giardia lamblia* class II FBPA is a zinc-dependent enzyme. In this study, we have explored the potential exploitation of the *Giardia* FBPA as a drug target. First, synthesis of FBPA was demonstrated in *Giardia* trophozoites by using an antibody-based fluorescence assay. Second, inhibition of FBPA gene transcription in *Giardia* trophozoites suggested that the enzyme is necessary for the survival of the organism under optimal laboratory growth conditions. Third, two crystal structures of FBPA in complex with the transition state analog phosphoglycolohydroxamate (PGH) show that the enzyme is homodimeric and that its active site contains a zinc ion. In one crystal form, each subunit contains PGH, which is coordinated to the zinc ion through the hydroxamic acid hydroxyl and carbonyl oxygen atoms. The second crystal form contains PGH only in one subunit and the active site of the second subunit is unoccupied. Inspection of the two states of the enzyme revealed that it undergoes a conformational transition upon ligand binding. The enzyme cleaves d-fructose-1,6-bisphosphate but not D-tagatose-1,6-bisphosphate, which is a tight binding competitive inhibitor. The essential role of the active site residue Asp-83 in catalysis was demonstrated by amino acid replacement. Determinants of catalysis and substrate recognition, derived from comparison of the *G. lamblia* FBPA structure with *Escherichia coli* FBPA and with a closely related enzyme, *E. coli* tagatose-1,6-bisphosphate aldolase (TBPA), are described.

*Giardia lamblia*, a flagellated protozoan, is the most common disease-causing parasite in developed countries. *G. lamblia* is also responsible for the most frequently diagnosed infective disease in developing countries (for a recent review see Ref. 1). The manifestations of giardiasis disease range from severe diarrhea, weight loss, vomiting, and malnutrition to asymptomatic carriage. *G. lamblia* is an ancient eukaryote. Its cellular biology and biochemistry are not well defined, and as a result, there is much to learn about its survival and adaptation tactics. Currently, giardiasis is treated by using metronidazole or tinidazole. Although the cure rates using tinidazole and metronidazole drug therapy are presently in excess of 60%, it is clear that alternative drug treatments are needed. Both drugs produce undesirable side effects, and increasing resistance to drug regimes presents a potential problem (2–6). Recurrence is also a problem, with frequency reported to be as high as 90% (4). In pursuit of alternative drug therapies, we have examined the recently reported *G. lamblia* genome sequence (7) in order to uncover genes that encode optimal targets.

This analysis has led to our interest in the *G. lamblia* fructose-1,6-bisphosphate aldolase (EC 4.1.2.13) (gFBPA), an enzyme that catalyzes the reversible cleavage of d-fructose 1,6-bisphosphate (FBP) to dihydroxyacetone phosphate (DHAP) and d-glyceraldehyde 3-phosphate (G3P) (Fig. 1A). This process is a key step in the classical Embden-Meyerhof-Parnas glycolytic pathway. Because *G. lamblia* lacks mitochondria as well as the components of oxidative phosphorylation, glucose degradation via glycolysis serves as its major source of ATP (8–10). We envisioned that selective inhibition of FBPA might disrupt the functioning of the glycolytic pathway and thereby hinder survival of *G. lamblia* within its human host. Unlike the mammalian FBPA, which is a class I aldolase, gFBPA belongs to the class II family (11). The former FBPA uses an active site lysine residue to activate the substrate for C(3)–C(4) bond cleavage via Schiff base formation (Fig. 2). In con-
Structure of Giardia Fructose-1,6-bisphosphate Aldolase

Contrast, class II FBPAs use a Zn$^{2+}$ cofactor to coordinate both the C(2) carbonyl and C(3) hydroxyl oxygens of the substrate, consequently stabilizing the enediolate intermediate formed by C(3)–C(4) bond cleavage (12, 13) (Fig. 2). Importantly, our genomic sequence analysis indicates that FBPA is the only Giardia class II aldolase and that the Giardia genome does not encode a class I aldolase.

The mechanistically dissimilar class I and II aldolases do not share significant amino acid sequence homology. The evolutionary significance of this finding has been discussed previously (12, 14). The divergence in class I and II aldolase structures and catalytic mechanisms suggests a novel strategy for the design of drugs that operate by selectively inhibiting the activity of FBPA in the G. lamblia parasite but not in mammalian FBPA.

To date, the most thoroughly characterized class II FBPA is the enzyme from Escherichia coli (ecFBPA). Crystal structures have been determined for apo-ecFBPA and for the enzyme complexed with a transition state analog, phosphoglycolohydroxamate (PGH) (Fig. 1B) (15, 16). The structures, together with kinetic properties of active site site-directed mutants, have provided significant insight into the class II FBPA catalytic mechanism (17–19). The class II FBPA adopts an (α/β)$_8$-barrel fold that supports a catalytic site at the C-terminal end of the barrel. The Zn$^{2+}$ coordinates the imidazole rings of His-110, His-226, and His-264 located at this site and with the C(2) = O and C(3) hydroxyl oxygen atoms of the substrate. In this manner, the coordinated Zn$^{2+}$ serves as an electron sink, stabilizing the enolate anion intermediate (17, 18) (Fig. 2).

ecFBPA exhibits very low activity toward the C(4) epimer of FBP, D-tagatose-1,6-bisphosphate (TBP), which is also a cellular metabolite (18). Because deprotonation of the C(4) hydroxyl initiates C(3)–C(4) bond cleavage (Fig. 2), it is likely that the FBP-TBP selectivity is the consequence of the orientation of the substrate relative to the general base. TBP is specifically targeted for cleavage by the E. coli D-tagatose-1,6-bisphosphate aldolase (ecTBPA), another class II aldolase. The crystal structures of ecFBPA (15, 16) and ecTBPA (20) are similar, yet the mechanism for substrate (i.e. stereoisomer) discrimination is not apparent from a comparison of the respective active sites. It is curious that the G. lamblia aldolase II shares greater sequence homology with the ecTBPA than it does with the ecFBPA.

In this study, we describe our studies of gFBPA, which is the first example of a eukaryotic class II aldolase to be characterized. The x-ray structure of the enzyme in complex with the Zn$^{2+}$ cofactor and PGH is reported, as are the kinetic constants for gFBPA catalysis of FBP and TBP cleavage. Finally, the essential role of the active site residue, Asp-83, in catalysis was confirmed by amino acid replacement and kinetic analysis of the mutant enzyme.

**MATERIALS AND METHODS**

Protein Cloning, Expression, and Purification—The trophozoites of the G. lamblia expression WB, clone 1267, were grown as described previously (21). The genomic DNA preparation was performed with the DNA Stat kit (Stratagene).

The PCR product was introduced into the pET100/d-TOPO expression vector (Invitrogen). Recombinant plasmids were isolated from the E. coli TOP10 strain (pET100/FBPAn).

For protein production, the E. coli strain BL21(DE3)Star was transformed with the pET100/FBPAn recombinant plasmid. Cells were grown in LB media at 30 °C to $A_{600} = 0.5$, when isopropyl 1-thio-β-d-galactopyranoside (0.1 mM) was added. After 3 h, cells were collected by centrifugation and suspended in 50 mM Tris-HCl (pH 8.5) and 10% glycerol. The cells were broken by passage through a French press. The soluble fraction was applied onto an anion exchange column, Sepharose Q (Amersham Biosciences). FBPA was eluted using a linear gradient of 0–0.5 M NaCl in 50 mM Tris-HCl (pH 8.5) and 5% glycerol. Concentrated protein fractions were applied onto a preparative gel filtration column, Sephacryl 100 (Amersham Biosciences). The remaining minor impurities were removed by using a hydrophobic column, phenyl-Sephacryl (Amer-
Sham Biosciences. The protein was eluted with a linear ammonium sulfate gradient (1.5-0 M), dialyzed against 20 mM Tris-HCl (pH 8.0) and 50 mM NaCl solution, concentrated to 12 mg/ml, flash-cooled in liquid nitrogen, and stored at −80 °C.

Preparation of D83A glFBPA Mutant—The QuickChange mutagenesis kit (Stratagene) was used in combination with the pET100/FBPA plasmid template and the E. coli strain BL21(DE3)Star cell line. The mutant sequence was confirmed by DNA sequencing. Homogeneous D83A glFBPA was prepared using the same procedure described above for the wild-type enzyme.

**Steady-state Kinetic Constant Determination**—Initial velocities were measured at 25 °C using 1-ml reaction solutions containing glFBPA (0.016 μM), 200 μM NADH, 5 units of triose-phosphate isomerase, 2 units of glycerol-3-phosphate dehydrogenase, and varying concentrations of FBP (Km, 0.5-10) in 50 mM Kgl-acetate (4.0-5.0), MES (5.5), BisTris (6.0-6.5), HEPES (7.0-8.0), TAPS (8.5), CHES (9.0-9.5), and CAPS (10.0-10.5). The absorbance of the reaction solution was monitored at 340 nm (ε = 6.2 mM⁻¹ cm⁻¹). For D83A glFBPA, a single velocity measurement was made using 170 μM protein and 2 mM FBP and monitoring the solution absorbance at 340 nm for 3 h. The velocity of wild-type glFBPA-catalyzed cleavage of TBP (supplied by Dr. Wolf-Dieter Fessner of Technische Universität, Darmstadt, Germany) was similarly measured using 3.5 mM TBP and 74 μM glFBPA.

To determine the kinetic constants, the initial velocity data were fitted to Equation 1 with KinetAsystI (IntelliKinetics, State College, PA),

\[
V_0 = \frac{V_{max}[S]}{(K_m + [S])}
\]  
(Eq. 1)

where [S] is the substrate concentration; \( V_0 \) is the initial velocity; \( V_{max} \) is the maximum velocity; and \( K_m \) is the Michaelis-Menten constant for the substrate. The \( k_{cat} \) value was calculated from \( V_{max} \) and the enzyme concentration \( [E] \) (determined employing the Bradford method (22)) using the equation \( k_{cat} = \frac{V_{max}}{[E]} \).

The competitive inhibition constants (\( K_i \)) of PGH (synthesized as the cyclohexylammonium chloride salt using a previously published protocol (23)) and TBP were determined by measuring the initial velocity of the above reactions at 0, 50, 100, and 150 nM PGH ([I]), and 6 and 20 μM TBP, and fitting the data to Equation 2 with KinetAsystI.

\[
V_0 = \frac{V_{max}[S]}{(K_m(1 + (I/K_i)) + [S])}
\]  
(Eq. 2)

**pH Rate Profile Determination**—The initial velocity data were measured as a function of the pH by using the following (50 mM) buffer at the indicated pH values: MES and potassium acetate (4.0–5.0), MES (5.5), BisTris (6.0–6.5), HEPES (7.0–8.0), TAPS (8.5), CHES (9.0–9.5), and CAPS (10.0–10.5). The \( k_{cat} \) and \( k_{cat}/K_{m} \) values were fitted to Equations 3 and 4, respectively, using the computer program KinetAsyst, to determine the values of \( k_{cat} \) or \( k_{cat}/K_{m} \).

\[
\log Y = \log(C/(1 + [H]/K_h + K_h/[H]))
\]  
(Eq. 3)

\[
\log Y = \log(C/(1 + [H]/K_h + K_h/[H] + [H]/K_h[K_h]))
\]  
(Eq. 4)

where \( Y \) is \( k_{cat} \) or \( k_{cat}/K_{m} \), [H] is the hydrogen ion concentration; \( C \) is the pH-independent value of \( k_{cat} \) or \( k_{cat}/K_{m} \), \( K_h \) is the acid dissociation constant; and \( K_b \) is the base dissociation constant.

**Analytical Size Exclusion Chromatography**—For estimation of the oligomeric state of the protein, analytical size exclusion chromatography was performed using a Superdex-200 HR 10/30 column (Amersham Biosciences). Runs were performed at a flow rate of 0.4 ml/min with 50 mM Tris-HCl (pH 7.5) and 0.1 M NaCl serving as eluant.

**Polyclonal Antibody Production and Immunofluorescence Assay**—Polyclonal antibodies against purified glFBPA were produced in BALB/c mice (Spring Valley Laboratories, Inc.). Fluorescein isothiocyanate-conjugated, affinity-purified goat anti-mouse immunoglobulin was used as the secondary antibody, and the control consisted of omission of the primary antibody. The specimens were examined with an Axioplan fluorescence microscope (Carl Zeiss, Thornwood, NY).

Functional Knock-out Experiments of the FBPA Gene in G. lamblia—The FBPA gene was inserted into the plasmid pdsRNA between two opposite tetracycline-inducible Ras-related nuclear GTP-binding protein (ran) promoters, and knock-out experiments were carried out as described previously (24).

**Crystallization and Data Collection**—Crystals were grown at room temperature in hanging drops using the vapor diffusion method. The protein solution was mixed with an equal volume of mother liquor containing 18–23% polyethylene glycol monomethyl ether 2000, 0.1 mM Tris-HCl (pH 8.8), and 0.2 mM MgCl₂. Hexagonal and orthorhombic crystals were obtained from protein solutions that were incubated on ice for 30 min with 20 mM PGH. The hexagonal crystals diffraction x-rays to a resolution of 2.3 Å. The orthorhombic crystals appeared within 4–8 weeks, and they diffracted x-rays to a resolution of 1.75 Å. For data collection, the crystals were transferred to solutions containing mother liquor and 20% glycerol and flash-cooled with liquid propane cooled in liquid nitrogen.

Diffraction data were acquired at the Industrial Macromolecular Crystallography Association-Collaborative Access Team (IMCA-CAT) 17-ID/GE beamlines at the Advanced Photon Source (Argonne National Laboratory, Argonne, IL). For data acquisition, the IMCA-CAT beamline was equipped with a Q210 CCD detector (ADSC, San Diego) or MARCCD 165 detector (Marresearch, Norderstedt, Germany). Data processing was carried out using HKL (25). The asymmetric unit of either crystal form contains two protein molecules. The statistics of data collection are provided in Table 1.

**Structure Determination and Refinement**—The structure of glFBPA was determined by molecular replacement using the program CNS (26) and the 2.3 Å diffraction data from the hexagonal crystal form. The search model was built based on E. coli tagatose-1,6-bisphosphate aldolase (ecFBPA), which shares 38% amino acid sequence identity with glFBPA (PDB entry 1GYF (20)). Structure refinement was carried out using the CNS program (26). The orthorhombic crystal form structure was obtained by molecular replacement using a partially refined structure of the hexagonal crystal form as the search model. The models were inspected and modified on a graphics work station using the program O (27). Water molecules were added to the model based on the Fo − Fc difference Fourier electron
Structure of Giardia Fructose-1,6-bisphosphate Aldolase

The sequencing of the *G. lamblia* genome is nearly complete (7). At the time of target selection, the list of *Saccharomyces cerevisiae* essential genes included 878 genes (32), comprising the most comprehensive cell viability data available for a eukaryotic organism. BlastP sequence analysis (33) of this list against the genome sequence of *G. lamblia* yielded 322 non-transmembrane proteins larger than 100 amino acid residues and that exhibit sequence homology to yeast essential genes with *E* score <10^-3.

The gene set was compared with the human genome data base (www.ncbi.nlm.nih.gov/genome/guide/human). One of the promising candidates that arose from this analysis was the gene encoding class II FBPA. In this context, it is noteworthy that *Plasmodium falciparum* and *Trypanosoma brucei* aldolases have been proposed as anti-malarial and anti-trypanosomal drug targets even though they belong to the class I enzymes and thus are closely related to the human enzyme (34, 35).

Expression and Characterization of glFBPA—To confirm that the gene encodes a true FBPA, the recombinant protein was expressed in *E. coli*. The theoretical mass of glFBPA is 35,376.9 Da, which is consistent with the mobility of the protein on SDs-polyacrylamide gels. Gel filtration analysis indicated that the protein is predominantly a homodimer in solution. Homodimeric association was also observed for ecFBPA (16), in contrast to FBPA from *Mycobacterium tuberculosis* (36) and *Thermus aquaticus* (37), and ecFBPA (20), which associate into homotetramers.

The steady-state kinetic constants for the glFBPA-catalyzed cleavage of FBP at pH 7.5 and 25°C in the absence of added ZnCl2 are *Km* = 3.55 ± 0.05 s^-1, *kcat* = 1.7 ± 0.1 μm, and *kcat/Km = 2.1 × 10^6 s^-1 m^-1*. These values are within the range determined for other FBPA (38).

Addition of ZnCl2 to reaction solutions did not increase the catalytic rate. In fact, at a concentration in excess of 30 μM ZnCl2, inhibition of catalysis was observed. This result suggested that the Zn2+ cofactor binds so tightly to glFBPA that the protein isolated from the *E. coli* cells is completely Zn2+-occupied. Moreover, attempts to remove the Zn2+ cofactor from glFBPA by exhaustive dialysis against EDTA in Zn2+-free buffer and then to restore catalytic activity by addition of Zn2+ were not successful. The dialyzed enzyme retained 50% of its original catalytic activity. The inclusion of ZnCl2 in the activity assay did not restore the lost activity.

The pH dependence of glFBPA catalysis was determined by measuring the *kcat* and *Km* values as a function of reaction pH. Both pH rate profiles (Fig. 3) are bell-shaped, indicating that loss of activity occurs at acidic and basic pH. Therefore, all further kinetic determinations were carried out at pH 7.5 where FBPA displays optimal activity. The pH profiles were fitted to define the apparent pH values reported in Fig. 3 legend.

Class II FBPA s are known to be inhibited by PGH (23), an inhibitor that mimics the endoelolate intermediate in the catalyzed reaction (Fig. 2). PGH is also known to inhibit triose-phosphate isomerase (23), which promotes the ensuing step in the glycolytic pathway. Consequently, PGH has little potential for drug targeting of the glFBPA within the human host. Nevertheless, PGH is an excellent probe for identification of the glFBPA active site residues via x-ray crystal structure determinations.

### Table 1

<table>
<thead>
<tr>
<th>X-ray data collection and refinement statistics</th>
<th>Hexagonal</th>
<th>Orthorhombic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data collection</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Space group</td>
<td>P61</td>
<td>C222_1</td>
</tr>
<tr>
<td>Cell dimension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a, b, c (Å)</td>
<td>62.4, 62.4, 319.9</td>
<td>90.0, 90.1, 166.1</td>
</tr>
<tr>
<td>Resolution range (Å)</td>
<td>30-2.3</td>
<td>30-1.75</td>
</tr>
<tr>
<td>No. of observations</td>
<td>127,478</td>
<td>334,755</td>
</tr>
<tr>
<td>No. of unique reflections</td>
<td>28,450</td>
<td>56,981</td>
</tr>
<tr>
<td>Completeness (%)</td>
<td>91.6 (77.9)</td>
<td>83.6 (75.2)</td>
</tr>
<tr>
<td>Rmerge (%)</td>
<td>0.037 (0.116)</td>
<td>0.059 (0.492)</td>
</tr>
<tr>
<td><strong>Refinement statistics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of reflections</td>
<td>28,450</td>
<td>56,981</td>
</tr>
<tr>
<td>No. of residues</td>
<td>605</td>
<td>595</td>
</tr>
<tr>
<td>No. of water molecules</td>
<td>368</td>
<td>440</td>
</tr>
<tr>
<td>Rmerge (%)</td>
<td>0.199</td>
<td>0.186</td>
</tr>
<tr>
<td>Rfree (%)</td>
<td>0.261</td>
<td>0.225</td>
</tr>
<tr>
<td><strong>Root mean square deviation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bonds (Å)</td>
<td>0.018</td>
<td>0.016</td>
</tr>
<tr>
<td>Angles (°)</td>
<td>2.0</td>
<td>1.8</td>
</tr>
<tr>
<td>Average B factor (Å2)</td>
<td>51.3</td>
<td>32.9</td>
</tr>
<tr>
<td><strong>Ramachandran plot (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Most favored</td>
<td>88.6</td>
<td>92.9</td>
</tr>
<tr>
<td>Allowed</td>
<td>11.0</td>
<td>6.7</td>
</tr>
<tr>
<td>Disallowed (Met-59)</td>
<td>0.4</td>
<td>0.4</td>
</tr>
</tbody>
</table>

* The values in parentheses are for the highest resolution shell.
* Rmerge = Σh|Fobs| - |Fcalc|/Σh|Fobs|, for equivalent reflections.
* Rcryst = Σh|Fobs| - |Fc|/Σh|Fobs|, where Fobs and Fc are the observed and calculated structure factors, respectively.
* Rfree is computed for 5% of reflections that were randomly selected and omitted from the refinement.
nation of the glFBPA-Zn$^{2+}$-PGH complex. The binding affinity for PGH to glFBPA is defined by $K_i = 37 \pm 2$ nM.

An analysis of glFBPA sequence homologs suggests that the enzyme is more closely related to the ecTBPA (TBP is a C(4) epimer of FBP) than it is to the ecFBPA (38 and 23% sequence identity, respectively). This finding prompted the evaluation of the enzymatic activity of glFBPA with TBP. The turnover rate for TBP is below the detection limit of the assay ($\leq 5.5 \times 10^{-5}$ s$^{-1}$). The binding affinity for TBP to glFBPA is reflected by the measured $K_i = 2.4 \pm 0.2$ μM.

In Vivo Enzyme Expression and Essentiality Test—Polyclonal antibodies raised against purified glFBPA were used in conjunction with a fluorescein isothiocyanate-conjugated secondary antibody to detect the expression of FBPA within G. lamblia trophozoites (Fig. 4). No fluorescence was observed for the control experiment in which trophozoites were treated with the fluorescein isothiocyanate-conjugated secondary antibody in the absence of primary antibody. These results show that the trophozoites produce FBPA in a form that is recognized by antibodies raised against the native enzyme and that the protein is distributed throughout the organism.

The requirement of the enzyme for the Giardia parasite viability was examined by carrying out an in vivo experiment. This involved RNA interference/antisense RNA gene silencing techniques (39), recently adapted to G. lamblia trophozoites (24). Within 10 days after cultivation, trophozoites transfected with the silencing plasmid yielded no viable organisms even prior to induction by tetracycline. In control experiments that employed the nonessential gene encoding adaptor protein 1 with approximate noncrystallographic 2-fold symmetry (Fig. 5). Each subunit (denoted A and B) folds into an (α/β)$_n$ barrel as seen in structures of other bacterial class II aldolases (15, 16, 20, 37).

In the hexagonal crystal form, the two subunits are similar, as reflected by the low root-mean-square deviation (r.m.s.d.) of their α-carbon positions (0.3 Å) when the two molecules are superimposed. The active site of each subunit is occupied by Zn$^{2+}$ and PGH. The first N-terminal residue of each molecule is not visible in the electron density map. In addition, no electron density is found to be associated with the surface residues 138–151, 181–189, and 323–324 in molecule A and 138–146, 184–188, and 323–324 in molecule B. These residues were omitted from the final model.

In the orthorhombic crystal form, the active site of one subunit (molecule A) is occupied by Zn$^{2+}$ and PGH, whereas the active site of molecule B is not. Superposition of the two subunits yields an r.m.s.d. value between α-carbon positions of 0.8 Å, showing that the inhibitor-bound and unbound states have different conformations. The first N-terminal residue of each subunit is not visible in the electron density map. In addition, no electron density is associated with the surface residues 138–151, 181–189, and 323–324 in molecule A and 138–146, 184–188, and 323–324 in molecule B. These residues were omitted from the final model.

The relatively large r.m.s.d. value between the ligand-bound and ligand-free molecules is the consequence of the fact that two loops, spanning residues 174–194 and residues 227–237,
have undergone conformational transitions. The conformational changes do not appear to be the result of crystal packing. Most notably, the 174–194 loop is largely disordered in the unbound state, whereas, with the exception of residues 186–189, the loop conformation is defined in the bound state. Upon ligand binding, the two loops adopt ordered conformations, with several residues stationed to shape the active site cavity. Key residues on the 174–194 loop are involved in PGH and Zn$^{2+}$ binding (Lys-182 and His-178) (Fig. 6). The 227–237 loop undergoes substantial rearrangement, with the Pro-231 C$^\alpha$ atom position at the tip of the loop shifting 5.7 Å from its position in the ligand-free structure.

The catalytic site zinc ion is shown as a green sphere, and PGH is shown in a red stick model.

The G3P site—The bound Zn$^{2+}$ has a trigonal bipyramidal coordination geometry similar to that seen in the crystal structures of ecFBPA and ecFBPA. Three Zn$^{2+}$ ligands are provided by the N$^\alpha$ atoms of His-84 and His-178, and the N$^\delta$ atom of His-210 (Fig. 7). The trigonal bipyramidal coordination is completed by the PGH N(OH) and C(1)O$^-$ groups. The distances between zinc-nitrogen and zinc-oxygen atoms are in the ranges of 2.1–2.3 and 2.5–2.6 Å, respectively. The exact positioning of two Zn$^{2+}$ imidazole ligands, those of His-84 and His-210, are fixed by networks of electrostatic interactions as follows: the side chain of His-84 interacts with one of the oxygen atoms of the Asp-105 carboxylate group. The other oxygen atom interacts with the main chain nitrogen atom of Ser-107. The side chain of His-210 interacts with the carboxylate group of Glu-133. The electrostatic network is extended further by the Glu-133 side chain via its interaction with the side chains of His-81 and Lys-251. In contrast to these two well anchored histidine residues, the imidazole of His-178, located on one of the flexible loops (encompassing residues 174–194), is not involved in an extended network of interactions. It is possible that anchoring the position of His-178 through extensive electrostatic interactions might interfere with the order-disorder transition that the loop undergoes during catalysis.

The DHAP site—The tight binding inhibitor PGH mimics the enediolate intermediate, which, in the ensuing step of catalysis, undergoes protonation to form DHAP (Fig. 2). The inhibitor binds in a deep polar cavity with the phosphate moiety stationed in a site enriched with the positive dipoles of four backbone amide groups (Gly-179, Ser-213, Asp-255, and Ser-256) (Fig. 6B). In addition, the phosphate group interacts with the amino group of Lys-182 on the 174–194 flexible loop and with the hydroxyl groups of Ser-213 and Ser-256. The phosphate-binding site is very similar to that present in ecFBPA and ecFBPA. An interesting difference between the bacterial aldolases and glFBPA is that the monovalent cation that counters the phosphate negative charge in the bacterial aldolases is absent in glFBPA. The cation is replaced by the ammonium substituent of the Lys-182 side chain. In addition to coordination with Zn$^{2+}$, the hydroxamate moiety of the PGH interacts with the backbone amide group of Gly-211, Asn-253, and Asp-83 (Fig. 6B). Asn-253 and Asp-83 are conserved in ecFBPA (numbered Asn-286 and Asp-109).

The G3P site—The interaction of groups in glFBPA with the G3P moiety was assessed by using a model of the enzyme-FBP complex (Fig. 7). In constructing this model, the PGH-binding mode was used to define the orientation of the DHAP-forming end of FBP and interactions with the G3P-forming end were optimized. Inspection of the model leads to the prediction that the inhibitor PGH, whereas the G3P site is unoccupied, and its properties are inferred based on a model of a bound intact substrate.

The structure of Giardia Fructose-1,6-bisphosphate Aldolase


### TABLE 2

<table>
<thead>
<tr>
<th>PDB code</th>
<th>Protein</th>
<th>Z score</th>
<th>r.m.s.d.</th>
<th>No. aligned residues</th>
<th>Sequence identity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1JVF</td>
<td>ecFBPA-PGH complex</td>
<td>40</td>
<td>1.2</td>
<td>270</td>
<td>42</td>
</tr>
<tr>
<td>1B5T</td>
<td>ecFBPA-PGH complex</td>
<td>32</td>
<td>1.9</td>
<td>269</td>
<td>24</td>
</tr>
<tr>
<td>1ZEN</td>
<td>ecFBPA</td>
<td>27</td>
<td>2.0</td>
<td>256</td>
<td>23</td>
</tr>
</tbody>
</table>

*a* The sequence identity corresponds to the structurally aligned residues.
Asp-83 binds the FBP through electrostatic interactions formed between the side chain carboxylate group and the substrate C(3) and C(4) hydroxyl groups. In addition, it suggests that Asp-83 functions to deprotonate the C(4) hydroxyl during catalytic turnover. To test this prediction, the D83A mutant was prepared and characterized. Although this mutant displays native protein behavior during purification, it does not have significant catalytic activity when subjected to forcing conditions (viz. 170 μM D83A FBPA with 2 mM FBP at pH 7.5 and 25 °C for 3 h). This condition defines a maximum turnover rate that is 5 orders of magnitude slower than the $k_{cat} = 3.55 \pm 0.05 \text{ s}^{-1}$ of the wild-type enzyme. The corresponding ecfBPA mutant D109A is also known to be catalytically impaired (17).

The properties of site-directed mutants of ecfBPA active site residues support the position of the G3P-forming end of the FBP. The studies indicate that Arg-331, Ser-61, Asp-288, and Asn-35 of the E. coli enzyme interact with the C(6) phosphate group and the C(4) and C(5) hydroxyl groups of FBP (17, 18, 42). Inspection of the gFBPA-FBP model leads to the prediction that the FBP C(6) phosphate interacts with the Ser-50 hydroxyl, guanidinium group of Arg-259 and guanidinium group of Arg-280 (located on the opposing subunit). The observation that both subunits contribute to the active site interactions has been noted in earlier studies with ecfBPA, where the counterpart of Arg-280 is Arg-331 (42). In contrast, Arg-259 of gFBPA does not have a counterpart in the ecfBPA. In ecfBPA this position is occupied by a glutamine (Gln-292). Consequently, it appears that the gFBPA active site contains a more extensive charge network. Specifically, Arg-259 is anchored by the two carboxyl groups of Asp-255 and Asp-278 (the latter residing on the partner subunit), and in turn, Asp-278 interacts with Arg-280 (Fig. 7).

Interaction of the G3P phosphate group with the hydroxyl group of Ser-50 is conserved in the class II FBP aldolases (Ser-61 in ecfBPA). This is an important interaction as indicated by characterization of the S61A ecfBPA mutant (18).

In the gFBPA-FBP model, the amide group of Asn-24 interacts with the G3P phosphate group as well as with the C(5) hydroxyl group of FBP. This is consistent with the observation that replacement of Asn-35, the corresponding residue in ecfBPA, by alanine results in impaired enzyme activity (17).

FIGURE 6. Binding of PGH to gFBPA. A, stereoscopic view of the electron density in the vicinity of the active site. Difference electron density map with the coefficients $F_o - F_c$ was calculated prior to inclusion of the PGH ligand in the model. The map is contoured at 3σ level. B, stereoscopic view of the environment of PGH. Atomic colors are as follows: oxygen, red; nitrogen, blue; carbon, gray; phosphor, orange; and zinc, steel blue. The carbon atoms of the PGH are colored in green. Key electrostatic interactions are shown as dashed lines.

The gFBPA-FBP-Zn$^{2+}$ active site model described above serves two purposes. First, it provides a starting point for inhibitor design. Second, it provides insight into why TBP is not recognized as a substrate.
Two different class II aldolases as follows: ecFBPA and ecTBPA.

The ecFBPA substrate discrimination factor, expressed as \((k_{\text{cat}}/K_m(\text{FBP}))/\left(k_{\text{cat}}/K_m(\text{TBP})\right)\), was determined to be 1423 (18). The ecTBPA substrate discrimination factor, expressed as \((k_{\text{cat}}/K_m(\text{TBP}))/\left(k_{\text{cat}}/K_m(\text{FBP})\right)\), is 333. Although the substrate specificity is not as high in the two *E. coli* aldolases as it is in the *gFBPA*, it is significant. Hunter and co-workers (20) identified Asp-288 and Gln-59 as residues that play an important role in discriminating between FBP and TBP substrates. In gFBPA, Asp-288 corresponds to Asp-255 and Gln-59 corresponds to Gln-48. In ecTBPA, the positions of these two residues are occupied by alanine (Fig. 8). The fact that gFBPA retains the “ecFBPA Asp-288” as Asp-255 is consistent with the substrate preference for FBP. Hunter and co-workers (20) suggested that Gln-59 might influence the side-chain orientation of another conserved residue positioned to contact FBP, Asn-35 (Asn-24 in ecTBPA and Asn-24 in gFBPA), and that the smaller alanine side chain leads to an alternate conformation of Asn-24 in TBPA. This conclusion is inconsistent with the observation that the active site arrangement of gFBPA has Asn-24 oriented in a nearly identical manner as that observed for Asn-24 in ecTBPA. Moreover, site-directed mutagenesis experiments that attempted to “switch” specificity failed to provide a clear-cut answer (18).

Clearly, there must be other factors involved in determining substrate specificity. Additional studies (e.g. structure of an enzyme-substrate complex with an ordered active site loop) are required to gain better insight into this issue.

**Conclusion**—We have identified the key glycolytic cycle enzyme FBPA as a potential *Giardia* drug target. The gFBPA, which belongs to the class II aldolase family, contrasts with the human FBPA that belongs to the evolutionarily unrelated class I aldolase family. We have shown that *Giardia* trophozoites produce this enzyme in the cytoplasm and that RNA silencing results in death of the parasite. Although both the amino acid sequence and crystal structure of gFBPA are more similar to those of ecTBPA than ecFBPA (38 and 23% sequence identity, respectively), the kinetic characterization shows unequivocally that the true substrate is FBP and that its C(4) epimer, TBP, is a gFBPA inhibitor. This finding underscores the importance of determining function experimentally rather than inferring it solely based on sequence/structure comparison.
Characterization, Kinetics, and Crystal Structures of Fructose-1,6-bisphosphate Aldolase from the Human Parasite, *Giardia lamblia*
Andrey Galkin, Liudmila Kulakova, Eugene Melamud, Ling Li, Chun Wu, Patrick Mariano, Debra Dunaway-Mariano, Theodore E. Nash and Osnat Herzberg

doi: 10.1074/jbc.M609534200 originally published online December 13, 2006

Access the most updated version of this article at doi: 10.1074/jbc.M609534200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 40 references, 6 of which can be accessed free at [http://www.jbc.org/content/282/7/4859.full.html#ref-list-1](http://www.jbc.org/content/282/7/4859.full.html#ref-list-1)